186 related articles for article (PubMed ID: 18712686)
1. Drug development research: the process.
Sataloff RT
Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
[No Abstract] [Full Text] [Related]
2. The process of drug development.
Burgess G
Surviv News (Atlanta Ga); 2002 Mar; ():18. PubMed ID: 11966191
[No Abstract] [Full Text] [Related]
3. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
4. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
5. Drug development: improving the process.
Peck CC
Food Drug Law J; 1997; 52(2):163-7. PubMed ID: 10557553
[No Abstract] [Full Text] [Related]
6. How are drugs approved? Part 3. The stages of drug development.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
[TBL] [Abstract][Full Text] [Related]
7. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
8. FDA aims to improve and streamline the drug development and review process.
Drug News Perspect; 2003; 16(1):40. PubMed ID: 12739551
[No Abstract] [Full Text] [Related]
9. Market watch: upcoming market catalysts in Q2 2011.
Jeng R
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226
[No Abstract] [Full Text] [Related]
10. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
11. FDA starts moving on critical path, but initiative running out of steam.
Finkelstein JB
J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
[No Abstract] [Full Text] [Related]
12. Disease models.
Gobburu J
Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
[No Abstract] [Full Text] [Related]
13. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
14. Science and regulatory rituals associated with the drug development process.
Versteegh LR
Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
[No Abstract] [Full Text] [Related]
15. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process.
Somberg JC; Borer JS
Am J Ther; 1999 May; 6(3):175-8. PubMed ID: 10423661
[No Abstract] [Full Text] [Related]
16. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
Grillo-López AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
[No Abstract] [Full Text] [Related]
17. Market watch: key clinical and regulatory events in Q2 2010.
Hay M
Nat Rev Drug Discov; 2010 Apr; 9(4):261. PubMed ID: 20357797
[No Abstract] [Full Text] [Related]
18. Obstacles and opportunities in new drug development.
Kaitin KI
Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
[No Abstract] [Full Text] [Related]
19. Advancing Alzheimer's disease drug review as a national priority.
Perry DP
Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
